Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1997 Dec;71(12):9475–9481. doi: 10.1128/jvi.71.12.9475-9481.1997

Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.

E Jurkiewicz 1, G Hunsmann 1, J Schäffner 1, T Nisslein 1, W Lüke 1, H Petry 1
PMCID: PMC230253  PMID: 9371609

Abstract

The sequence variability of viral structure polypeptides has been associated with immune escape mechanisms. The V1 region of simian immunodeficiency virus (SIV) is a highly variable region of the SIVmac env gene. Here, we describe the V1 region as a linear neutralizing epitope. V1 region-specific neutralizing antibodies (NAb) were first demonstrated in a rabbit infected with a recombinant vaccinia virus carrying the env gene of human immunodeficiency virus type 2 strain ben (HIV-2ben). Since we detected in this animal V1 region-specific NAb that were able to neutralize not only human immunodeficiency virus type 2 but also SIVmac32H, we investigated whether a similar immune response is evoked in macaques (Macaca mulatta) either infected with SIVmac or immunized with the external glycoprotein (gp130) of the same virus. Distinctly lower NAb titers were found in the SIVmac-infected animals than in the gp130-immunized macaques. Since the NAb titers in both groups were high enough for competition experiments, we used five overlapping peptides encompassing the whole V1 region for a detailed identification of the epitope. In each of the 12 macaques investigated, we detected a high level of NAb reacting with at least one peptide located in the central part of the V1 region. The relatively high degree of divergence, especially within the central part of the V1 region, which characterized the evolution of the retroviral sequences from the original inoculum in the infected macaques suggests the development of escape mutants. Furthermore, 3 of 12 animals developed NAb directed against the amino-terminal end of the V1 region epitope. Sequence analysis, however, revealed relatively low levels of genetic drift and genetic variability within this part of the V1 region. The induction of V1 env-specific NAb not only in gp130-immunized macaques but also in SIVmac-infected animals in combination with the increased genetic variability of this region in vivo indicates a marked biological significance of this epitope for the virus.

Full Text

The Full Text of this article is available as a PDF (179.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Almond N., Jenkins A., Heath A. B., Kitchin P. Sequence variation in the env gene of simian immunodeficiency virus recovered from immunized macaques is predominantly in the V1 region. J Gen Virol. 1993 May;74(Pt 5):865–871. doi: 10.1099/0022-1317-74-5-865. [DOI] [PubMed] [Google Scholar]
  2. Babas T., Belhadj-Jrad B., Le Grand R., Dormont D., Montagnier L., Bahraoui E. Specificity and neutralizing capacity of three monoclonal antibodies produced against the envelope glycoprotein of simian immunodeficiency virus isolate 251. Virology. 1995 Aug 1;211(1):339–344. doi: 10.1006/viro.1995.1414. [DOI] [PubMed] [Google Scholar]
  3. Benichou S., Legrand R., Nakagawa N., Faure T., Traincard F., Vogt G., Dormont D., Tiollais P., Kieny M. P., Madaule P. Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1992 Jun;8(6):1165–1170. doi: 10.1089/aid.1992.8.1165. [DOI] [PubMed] [Google Scholar]
  4. Broliden P. A., von Gegerfelt A., Clapham P., Rosen J., Fenyö E. M., Wahren B., Broliden K. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):461–465. doi: 10.1073/pnas.89.2.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chackerian B., Morton W. R., Overbaugh J. Persistence of simian immunodeficiency virus Mne variants upon transmission. J Virol. 1994 Jun;68(6):4080–4085. doi: 10.1128/jvi.68.6.4080-4085.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chanh T. C., Dreesman G. R., Kanda P., Linette G. P., Sparrow J. T., Ho D. D., Kennedy R. C. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 1986 Nov;5(11):3065–3071. doi: 10.1002/j.1460-2075.1986.tb04607.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Desrosiers R. C. The simian immunodeficiency viruses. Annu Rev Immunol. 1990;8:557–578. doi: 10.1146/annurev.iy.08.040190.003013. [DOI] [PubMed] [Google Scholar]
  8. Emini E. A., Nara P. L., Schleif W. A., Lewis J. A., Davide J. P., Lee D. R., Kessler J., Conley S., Matsushita S., Putney S. D. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol. 1990 Aug;64(8):3674–3678. doi: 10.1128/jvi.64.8.3674-3678.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Emini E. A., Schleif W. A., Nunberg J. H., Conley A. J., Eda Y., Tokiyoshi S., Putney S. D., Matsushita S., Cobb K. E., Jett C. M. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 1992 Feb 20;355(6362):728–730. doi: 10.1038/355728a0. [DOI] [PubMed] [Google Scholar]
  10. Fung M. S., Sun C. R., Gordon W. L., Liou R. S., Chang T. W., Sun W. N., Daar E. S., Ho D. D. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol. 1992 Feb;66(2):848–856. doi: 10.1128/jvi.66.2.848-856.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gorny M. K., Moore J. P., Conley A. J., Karwowska S., Sodroski J., Williams C., Burda S., Boots L. J., Zolla-Pazner S. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol. 1994 Dec;68(12):8312–8320. doi: 10.1128/jvi.68.12.8312-8320.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Goudsmit J., Debouck C., Meloen R. H., Smit L., Bakker M., Asher D. M., Wolff A. V., Gibbs C. J., Jr, Gajdusek D. C. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478–4482. doi: 10.1073/pnas.85.12.4478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Haigwood N. L., Misher L., Chin S. M., Blair M., Planelles V., Scandella C. J., Steimer K. S., Gardner M. B., Yilma T., Hirsch V. M. Characterization of group specific antibodies in primates: studies with SIV envelope in macaques. J Med Primatol. 1992 Feb-May;21(2-3):82–90. [PubMed] [Google Scholar]
  14. Harada S., Purtilo D. T., Koyanagi Y., Sonnabend J., Yamamoto N. Sensitive assay for neutralizing antibodies against AIDS-related viruses (HTLV-III/LAV). J Immunol Methods. 1986 Sep 27;92(2):177–181. doi: 10.1016/0022-1759(86)90163-8. [DOI] [PubMed] [Google Scholar]
  15. Hartmann H., Vogt M. W., Durno A. G., Hirsch M. S., Hunsmann G., Eckstein F. Enhanced in vitro inhibition of HIV-1 replication by 3'-fluoro-3'-deoxythymidine compared to several other nucleoside analogs. AIDS Res Hum Retroviruses. 1988 Dec;4(6):457–466. doi: 10.1089/aid.1988.4.457. [DOI] [PubMed] [Google Scholar]
  16. Ho D. D., Fung M. S., Cao Y. Z., Li X. L., Sun C., Chang T. W., Sun N. C. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8949–8952. doi: 10.1073/pnas.88.20.8949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ho D. D., Sarngadharan M. G., Hirsch M. S., Schooley R. T., Rota T. R., Kennedy R. C., Chanh T. C., Sato V. L. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol. 1987 Jun;61(6):2024–2028. doi: 10.1128/jvi.61.6.2024-2028.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Javaherian K., Langlois A. J., McDanal C., Ross K. L., Eckler L. I., Jellis C. L., Profy A. T., Rusche J. R., Bolognesi D. P., Putney S. D. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768–6772. doi: 10.1073/pnas.86.17.6768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Javaherian K., Langlois A. J., Montefiori D. C., Kent K. A., Ryan K. A., Wyman P. D., Stott J., Bolognesi D. P., Murphey-Corb M., Larosa G. J. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein. J Virol. 1994 Apr;68(4):2624–2631. doi: 10.1128/jvi.68.4.2624-2631.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Javaherian K., Langlois A. J., Schmidt S., Kaufmann M., Cates N., Langedijk J. P., Meloen R. H., Desrosiers R. C., Burns D. P., Bolognesi D. P. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1418–1422. doi: 10.1073/pnas.89.4.1418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Jurkiewicz E., Panse P., Jentsch K. D., Hartmann H., Hunsmann G. In vitro anti-HIV-1 activity of chondroitin polysulphate. AIDS. 1989 Jul;3(7):423–427. doi: 10.1097/00002030-198907000-00003. [DOI] [PubMed] [Google Scholar]
  22. Jurkiewicz E., Petry H., Sutor G. C., Lang S., Schedel I., Hunsmann G. HIV-1 cross-neutralizing antibodies in German HIV-1-infected patients do not correlate with an antibody-binding pattern against different HIV-1 isolates. AIDS. 1995 Jan;9(1):91–93. [PubMed] [Google Scholar]
  23. Kayman S. C., Wu Z., Revesz K., Chen H., Kopelman R., Pinter A. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J Virol. 1994 Jan;68(1):400–410. doi: 10.1128/jvi.68.1.400-410.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kent K. A., Kitchin P., Mills K. H., Page M., Taffs F., Corcoran T., Silvera P., Flanagan B., Powell C., Rose J. Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251. AIDS Res Hum Retroviruses. 1994 Feb;10(2):189–194. doi: 10.1089/aid.1994.10.189. [DOI] [PubMed] [Google Scholar]
  25. Kent K. A., Rud E., Corcoran T., Powell C., Thiriart C., Collignon C., Stott E. J. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res Hum Retroviruses. 1992 Jun;8(6):1147–1151. doi: 10.1089/aid.1992.8.1147. [DOI] [PubMed] [Google Scholar]
  26. Kikukawa R., Koyanagi Y., Harada S., Kobayashi N., Hatanaka M., Yamamoto N. Differential susceptibility to the acquired immunodeficiency syndrome retrovirus in cloned cells of human leukemic T-cell line Molt-4. J Virol. 1986 Mar;57(3):1159–1162. doi: 10.1128/jvi.57.3.1159-1162.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kirchhoff F., Jentsch K. D., Bachmann B., Stuke A., Laloux C., Lüke W., Stahl-Hennig C., Schneider J., Nieselt K., Eigen M. A novel proviral clone of HIV-2: biological and phylogenetic relationship to other primate immunodeficiency viruses. Virology. 1990 Jul;177(1):305–311. doi: 10.1016/0042-6822(90)90484-9. [DOI] [PubMed] [Google Scholar]
  28. Kodama T., Burns D. P., Silva D. P., Veronese F. D., Desrosiers R. C. Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus. J Virol. 1991 Apr;65(4):2010–2018. doi: 10.1128/jvi.65.4.2010-2018.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. LaRosa G. J., Davide J. P., Weinhold K., Waterbury J. A., Profy A. T., Lewis J. A., Langlois A. J., Dreesman G. R., Boswell R. N., Shadduck P. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science. 1990 Aug 24;249(4971):932–935. doi: 10.1126/science.2392685. [DOI] [PubMed] [Google Scholar]
  30. Lewis M. G., Elkins W. R., McCutchan F. E., Benveniste R. E., Lai C. Y., Montefiori D. C., Burke D. S., Eddy G. A., Shafferman A. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine. 1993 Oct;11(13):1347–1355. doi: 10.1016/0264-410x(93)90106-8. [DOI] [PubMed] [Google Scholar]
  31. Luke W., Coulibaly C., Dittmer U., Voss G., Oesterle R., Makoschey B., Sauermann U., Jurkiewicz E., Stahl-Henning C., Petry H. Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo. Virology. 1996 Feb 15;216(2):444–450. doi: 10.1006/viro.1996.0082. [DOI] [PubMed] [Google Scholar]
  32. Matsumi S., Matsushita S., Yoshimura K., Javaherian K., Takatsuki K. Neutralizing monoclonal antibody against a external envelope glycoprotein (gp110) of SIVmac251. AIDS Res Hum Retroviruses. 1995 Apr;11(4):501–508. doi: 10.1089/aid.1995.11.501. [DOI] [PubMed] [Google Scholar]
  33. McBride B. W., Corthals G., Rud E., Kent K., Webster S., Cook N., Cranage M. P. Comparison of serum antibody reactivities to a conformational and to linear antigenic sites in the external envelope glycoprotein of simian immunodeficiency virus (SIVmac) induced by infection and vaccination. J Gen Virol. 1993 Jun;74(Pt 6):1033–1041. doi: 10.1099/0022-1317-74-6-1033. [DOI] [PubMed] [Google Scholar]
  34. Miyoshi I., Kubonishi I., Yoshimoto S., Akagi T., Ohtsuki Y., Shiraishi Y., Nagata K., Hinuma Y. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature. 1981 Dec 24;294(5843):770–771. doi: 10.1038/294770a0. [DOI] [PubMed] [Google Scholar]
  35. Moore J. P., Sattentau Q. J., Yoshiyama H., Thali M., Charles M., Sullivan N., Poon S. W., Fung M. S., Traincard F., Pinkus M. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains. J Virol. 1993 Oct;67(10):6136–6151. doi: 10.1128/jvi.67.10.6136-6151.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Rüker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993 Nov;67(11):6642–6647. doi: 10.1128/jvi.67.11.6642-6647.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Otteken A., Voss G., Hunsmann G. Mapping of the human immunodeficiency virus type 2 envelope glycoprotein CD4 binding region and fusion domain with truncated proteins expressed by recombinant vaccinia viruses. Virology. 1993 May;194(1):37–43. doi: 10.1006/viro.1993.1232. [DOI] [PubMed] [Google Scholar]
  38. Overbaugh J., Rudensey L. M. Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques. J Virol. 1992 Oct;66(10):5937–5948. doi: 10.1128/jvi.66.10.5937-5948.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Overbaugh J., Rudensey L. M., Papenhausen M. D., Benveniste R. E., Morton W. R. Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J Virol. 1991 Dec;65(12):7025–7031. doi: 10.1128/jvi.65.12.7025-7031.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Palker T. J., Clark M. E., Langlois A. J., Matthews T. J., Weinhold K. J., Randall R. R., Bolognesi D. P., Haynes B. F. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932–1936. doi: 10.1073/pnas.85.6.1932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Palker T. J., Muir A. J., Spragion D. E., Staats H. F., Langlois A., Montefiori D. C. The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope. Virology. 1996 Oct 15;224(2):415–426. doi: 10.1006/viro.1996.0548. [DOI] [PubMed] [Google Scholar]
  42. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods. 1988 Aug;20(4):309–321. doi: 10.1016/0166-0934(88)90134-6. [DOI] [PubMed] [Google Scholar]
  43. Petry H., Dittmer U., Stahl-Hennig C., Coulibaly C., Makoschey B., Fuchs D., Wachter H., Tolle T., Morys-Wortmann C., Kaup F. J. Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection. J Virol. 1995 Mar;69(3):1564–1574. doi: 10.1128/jvi.69.3.1564-1574.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Putkonen P., Thorstensson R., Ghavamzadeh L., Albert J., Hild K., Biberfeld G., Norrby E. Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature. 1991 Aug 1;352(6334):436–438. doi: 10.1038/352436a0. [DOI] [PubMed] [Google Scholar]
  45. Robert-Guroff M., Aldrich K., Muldoon R., Stern T. L., Bansal G. P., Matthews T. J., Markham P. D., Gallo R. C., Franchini G. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates. J Virol. 1992 Jun;66(6):3602–3608. doi: 10.1128/jvi.66.6.3602-3608.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Rudensey L. M., Kimata J. T., Benveniste R. E., Overbaugh J. Progression to AIDS in macaques is associated with changes in the replication, tropism, and cytopathic properties of the simian immunodeficiency virus variant population. Virology. 1995 Mar 10;207(2):528–542. doi: 10.1006/viro.1995.1113. [DOI] [PubMed] [Google Scholar]
  47. Rusche J. R., Javaherian K., McDanal C., Petro J., Lynn D. L., Grimaila R., Langlois A., Gallo R. C., Arthur L. O., Fischinger P. J. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A. 1988 May;85(9):3198–3202. doi: 10.1073/pnas.85.9.3198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Schneider J., Lüke W., Kirchhoff F., Jung R., Jurkiewicz E., Stahl-Hennig C., Nick S., Klemm E., Jentsch K. D., Hunsmann G. Isolation and characterization of HIV-2ben obtained from a patient with predominantly neurological defects. AIDS. 1990 May;4(5):455–457. doi: 10.1097/00002030-199005000-00012. [DOI] [PubMed] [Google Scholar]
  49. Schäffner J. W., Dittmer U., Otteken A., Coulibaly C., Bodemer W., Voss G., Hunsmann G. Comparison of humoral immunity and induction of proliferating T lymphocytes in vaccinia virus-infected rabbits and rhesus macaques. Am J Vet Res. 1994 Sep;55(9):1250–1255. [PubMed] [Google Scholar]
  50. Silvera P., Flanagan B., Kent K., Rud E., Powell C., Corcoran T., Bruck C., Thiriart C., Haigwood N. L., Stott E. J. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques. AIDS Res Hum Retroviruses. 1994 Oct;10(10):1295–1304. doi: 10.1089/aid.1994.10.1295. [DOI] [PubMed] [Google Scholar]
  51. Stahl-Hennig C., Coulibaly C., Petry H., Voss G., Dittmer U., Bodemer W., Makoschey B., Jurkiewicz E., Lüke W., Hunsmann G. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo. AIDS Res Hum Retroviruses. 1994;10 (Suppl 2):S27–S32. [PubMed] [Google Scholar]
  52. Stahl-Hennig C., Voss G., Dittmer U., Coulibaly C., Petry H., Makoschey B., Cranage M. P., Aubertin A. M., Lüke W., Hunsmann G. Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus. AIDS. 1993 Jun;7(6):787–795. doi: 10.1097/00002030-199306000-00005. [DOI] [PubMed] [Google Scholar]
  53. Sullivan N., Thali M., Furman C., Ho D. D., Sodroski J. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J Virol. 1993 Jun;67(6):3674–3679. doi: 10.1128/jvi.67.6.3674-3679.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Sutor G. C., Dreikhausen U., Vähning U., Jurkiewicz E., Hunsmann G., Lundin K., Schedel I. Neutralization of HIV-1 by anti-idiotypes to monoclonal anti-CD4. Potential for idiotype immunization against HIV. J Immunol. 1992 Aug 15;149(4):1452–1461. [PubMed] [Google Scholar]
  55. Tolle T., Petry H., Bachmann B., Hunsmann G., Lüke W. Variability of the env gene in cynomolgus macaques persistently infected with human immunodeficiency virus type 2 strain ben. J Virol. 1994 Apr;68(4):2765–2771. doi: 10.1128/jvi.68.4.2765-2771.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Torres J. V., Malley A., Banapour B., Anderson D. E., Axthelm M. K., Gardner M. B., Benjamini E. An epitope on the surface envelope glycoprotein (gp130) of simian immunodeficiency virus (SIVmac) involved in viral neutralization and T cell activation. AIDS Res Hum Retroviruses. 1993 May;9(5):423–430. doi: 10.1089/aid.1993.9.423. [DOI] [PubMed] [Google Scholar]
  57. Voss G., Dittmer U., Coulibaly C., Makoschey B., Petry H., Lüke W., Hunsmann G. Differences in the B and T cell immune response to the envelope glycoprotein 130 (gp130) of the macaque strain of simian immunodeficiency virus (SIVmac), induced by immunization of rhesus macaques with virus-derived or vaccinia virus-expressed gp130. J Gen Virol. 1993 Sep;74(Pt 9):1757–1763. doi: 10.1099/0022-1317-74-9-1757. [DOI] [PubMed] [Google Scholar]
  58. Voss G., Stahl-Hennig C., Petry H., Coulibaly C., Nick S., Fuchs D., Wachter H., Lüke W., Hunsmann G. Immunization of rhesus monkeys with high- and low-dose Tween-ether-disrupted SIVMAC. AIDS Res Hum Retroviruses. 1992 Aug;8(8):1397–1400. doi: 10.1089/aid.1992.8.1397. [DOI] [PubMed] [Google Scholar]
  59. Wendler I., Bienzle U., Hunsmann G. Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Hum Retroviruses. 1987 Summer;3(2):157–163. doi: 10.1089/aid.1987.3.157. [DOI] [PubMed] [Google Scholar]
  60. Wu Z., Kayman S. C., Honnen W., Revesz K., Chen H., Vijh-Warrier S., Tilley S. A., McKeating J., Shotton C., Pinter A. Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J Virol. 1995 Apr;69(4):2271–2278. doi: 10.1128/jvi.69.4.2271-2278.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES